Aeruginosin 865

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Aeruginosin 865 

Aeruginosin 865 是从地面蓝藻 Nostoc sp. Lukešová 30/93 分离出来的,是首个同时含有脂肪酸和碳水化合物的铜绿素蛋白型肽。Aeruginosin 865 抑制 NF-kB 向核的转运。Aeruginosin 865 具有抗炎作用。

Aeruginosin 865

Aeruginosin 865 Chemical Structure

CAS No. : 1611990-01-2

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

Aeruginosin 865 相关产品

同靶点产品:

同靶点蛋白产品:

生物活性

Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of NF-kB to the nucleus. Aeruginosin 865 has anti-inflammatory effect[1]

体外研究
(In Vitro)

Aeruginosin 865 (pretreatment with 0.1-100 μg/mL) shows significant inhibition of IL-8 (EC50=3.5 μg/mL) and ICAM-1 (EC50=50.0 μg/mL) in hTNF-α-stimulated HLMVECs in a concentration-dependent manner. Aeruginosin 865 does not affect cell viability, even at much higher concentration in HeLa, HepG2 cells[1].
Aeruginosin 865 (100-200 μM) shows high-dose cytotoxicity in Mouse fibrosarcoma cells and with no cytotoxic effect in NIH/3T3 cells[2].
.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Aeruginosin 865 相关抗体:

分子量

864.98

Formula

C41H64N6O14

CAS 号

1611990-01-2

结构分类
  • Phenols
  • Monophenols
  • Others
初始来源
  • 微生物

Terrestrial cyanobacterium Nostoc sp

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
Data Sheet (534 KB) 产品使用指南 (1538 KB)

参考文献
  • [1]. Aleksandra Kapuścik, et al. Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem. 2013 Nov 25;14(17):2329-37.  [Content Brief]

    [2]. Ivana Veselá, et al. Cytotoxic Effect of Aeruginosin-865, Resveratrol and Capsaicin on Mouse Fibroblasts and Cells Derived from Fallow Deer. Natural Product Communications, Volume: 13 issue: 2.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务